A multicenter, randomized, placebo-controlled, double-blind, comparative study of dienogest at 1 mg/day in patients with primary and secondary dysmenorrhea

Yutaka Osuga, Koichi Hayashi, Kôichi Hayashi, Shingo Kanda
Fertility and sterility · 2020 · vol. 113(3) , pp. 627–635.e1 · doi:10.1016/j.fertnstert.2019.11.010 · PMID:32192595 · W3012275361
RCT OA: bronze CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study evaluated dienogest at 1 mg/day in patients with primary and secondary dysmenorrhea through a multicenter, randomized, placebo-controlled, double-blind design.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with primary and secondary dysmenorrhea. DESIGN: Phase III, randomized, double-blind, multicenter, placebo-controlled study. SETTING: Clinical study sites in Japan. PATIENT(S): Ninety-four women with dysmenorrhea. INTERVENTION(S): Random assignment to receive DNG (1 mg/day, orally) or placebo for 12 weeks; patients treated for anemia before randomization in cases of complicated anemia. MAIN OUTCOME MEASURE(S): Change in the dysmenorrhea score from baseline to week 12 of treatment with visual analog scale used for pain assessment. RESULT(S): The DNG group was superior to the placebo group in terms of the change from baseline in the dysmenorrhea score at week 12 of treatment in patients with dysmenorrhea. In both primary and secondary dysmenorrhea, the DNG group was superior to the placebo group for each diagnostic category. The mean serum estradiol concentrations were similar between the DNG and the placebo groups. Although the incidence of irregular uterine bleeding was higher in the DNG group, there were no severe or serious events. Most events of genital bleeding were spotting or breakthrough bleeding, suggesting DNG was well tolerated. CONCLUSION(S): In both primary and secondary dysmenorrhea, DNG at 1 mg/day relieved pain and was well tolerated. CLINICAL TRIAL REGISTRATION NUMBER: JapicCTI-173547(en).

My notes (saved in your browser only)

Condition tags

dysmenorrhea

MeSH descriptors

Dysmenorrhea Nandrolone Administration, Oral Adult Back Pain Back Pain Back Pain Back Pain Dosage Forms Double-Blind Method Dysmenorrhea Dysmenorrhea Dysmenorrhea Female Humans Japan Japan Nandrolone Nandrolone Nandrolone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-14T06:27:26.827241+00:00
pubmed
last seen: 2026-10-08T21:27:00.370498+00:00
License: CC0 · commercial use OK